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Background: Fatty acid amide hydrolase 2 (FAAH2) is a hydrolase that mediates the degradation of endocannabinoids
in man. Alterations in the endocannabinoid system are associated with a wide variety of neurologic and psychiatric
conditions, but the phenotype and biochemical characterization of patients with genetic defects of FAAH2 activity
have not previously been described. We report a male with autistic features with an onset before the age of 2 years
who subsequently developed additional features including anxiety, pseudoseizures, ataxia, supranuclear gaze palsy, and
isolated learning disabilities but was otherwise cognitively intact as an adult.
Methods and results: Whole exome sequencing identified a rare missense mutation in FAAH2, hg19: g.57475100G > T
(c.1372G > T) resulting in an amino acid change (p.Ala458Ser), which was Sanger confirmed as maternally inherited and
absent in his healthy brother. Alterations in lipid metabolism with abnormalities of the whole blood acyl carnitine
profile were found. Biochemical and molecular modeling studies confirmed that the p.Ala458Ser mutation results in
partial inactivation of FAAH2. Studies in patient derived fibroblasts confirmed a defect in FAAH2 activity resulting in
altered levels of endocannabinoid metabolites.
Conclusions: We propose that genetic alterations in FAAH2 activity contribute to neurologic and psychiatric disorders
in humans.
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The endocannabinoid system (ECS) is a complex neural sig-
naling system that is implicated in a wide variety of normal
and pathological neurological processes. Although activation
of the ECS has been proposed to have neuroprotective effects
in a number of disease states, abnormal activation of the ECS
can also be neurotoxic [1] and alterations in the ECS have been
implicated in a number of neurological diseases including
Parkinson’s disease [2], Huntington’s disease [3], multiple
sclerosis [4] and Fragile X syndrome [5]. Alterations in* Correspondence: cvankarnebeek@cw.bc.ca
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unless otherwise stated.endocannabinoid signaling have also been implicated in awide
variety of psychiatric conditions including anxiety, depression,
schizophrenia [6-14] and autistic spectrumdisorders [15,16].
The endocannabinoids anandamide (AEA) and 2-
arachidonoylglycerol (2-AG) are degraded by a series of
four hydrolases in man [17]. Alterations in endocannabi-
noid activity can occur through altered receptor binding
[8], alterations in metabolic enzymes [18] or downstream
pathways [13]. Fatty acid amide hydrolase (FAAH1; [MIM
606581]) is the principal enzyme that hydrolyzes AEA in
mammals [18]. Missense variants in FAAH1 have been as-
sociated with schizophrenia in genome-wide associated
studies [19] and homozygosity for a common polymorph-
ism in FAAH1 reduces functional activity of the enzyme
and is associated with problem drug use [20] which is ais is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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enzyme (FAAH2 [MIM 300654]), present in man but not
rodents, was identified and shown to mediate endocanna-
binoid degradation [21,22]. Inhibition of FAAH1 or
FAAH2 would be expected to increase levels of endocan-
nabinoids available for receptor binding. The ECS is impli-
cated in neural development [10] and overactivation of
the ECS during pregnancy has been associated with
growth and neurocognitive deficits in human offspring
[23-25]. Thus it is conceivable that mutations that affect
FAAH2 enzyme activity could result in a neurologic or
psychiatric phenotype.
The FAAH2 gene resides on the X chromosome in
man and has been identified in recent genome wide as-
sociation studies as a possible candidate gene for X-
linked intellectual disability [26] and autism spectrum
disorders [27]. Here, we present a novel case where a
male patient with neurologic and psychiatric symptoms
was shown to harbor a distinct missense variant in the
FAAH2 gene. Using a variety of techniques, we provide
evidence that this mutation compromises FAAH2 activ-
ity and propose that this alteration in endocannabinoid
signaling may be the cause of the phenotype observed in
this patient.Methods
Ethical issues
This study was initiated as part of the Treatable Intellectual
Disability Endeavor in British Columbia. Informed consent
was obtained from the individuals involved in this study
and approved by the ethics committees of the University of
British Columbia (Vancouver, Canada).Whole exome sequencing
Genomic DNA was isolated from the peripheral blood
of the patient, unaffected brother, as well as parents
using standard techniques. Whole exome sequencing
was performed for all four family members using the Ion
AmpliSeq™ Exome Kit and Ion Proton™ System from Life
Technologies (Next Generation Sequencing Services,
UBC, Vancouver, Canada). An in-house designed bio-
informatics pipeline [28] was used to align the reads to
the human reference genome version hg19 and to iden-
tify and assess rare variants for their potential to disrupt
protein function. The average coverage was 100X. Rare
variants were identified based on a comparison against
alleleic frequencies from dbSNPv138, Exome Variant
Server and an in-house database of more than 260
exomes and genomes using minor allele frequency
(MAF) as <1% as the threshold. The remaining variants
were subsequently screened under a series of genetic
models described in the text. We have submitted the
FAAH2 missense variant to the LSDB gene variantdatabase (http://grenada.lumc.nl/LOVD2/MR/variants?
action=search_unique&select_db=FAAH2).
Cloning and transfections
Human FAAH1 (NM_001441) and FAAH2 (NM_174912)
cDNAs were subcloned into pcDNA4 expression vectors.
A FLAG epitope tag was inserted in the C-terminus of
FAAH2. Site-directed mutagenesis was performed using
Quikchange. All constructs were verified by DNA sequen-
cing. Human 293T cells and primary fibroblasts were cul-
tured in DMEM supplemented with 10% fetal bovine
serum, 100 U/ml penicillin/streptomycin, and 2 mM L-
glutamine. Transfections were performed using the GenJet
Plus transfection reagent (SignaGen, Rockville, MD) ac-
cording to the manufacturer’s instructions.
Western blotting
Western blot experiments were performed exactly as
described [29]. Blots were probed mouse anti-FAAH1
(1:1000, Abcam #Ab54615), mouse anti-GAPDH (1:5000,
Abcam #Ab8245), mouse anti-FLAG (1:1000, Sigma #F1804),
or rabbit anti-FAAH2 (1:200, Abcam #Ab103724)
antibodies. The blots were then incubated with the re-
spective goat anti-mouse or goat anti-rabbit IgG
HRP-conjugated antibodies (Life Technologies), devel-
oped using the Immun-star HRP substrate (Bio-Rad), and
scanned using a C-DiGiT scanner (Li-COR).
Enzyme assays
Enzyme assays using [14C]AEA or [14C]PEA as substrates
were performed exactly as described [22].
Endocannabinoid quantification in fibroblasts
Endocannabinoid levels were quantified exactly as de-
scribed [30]. Briefly, two million affected and unaffected
fibroblasts were harvested and the lipids extracted by
addition of 2:1:1 chloroform:methanol:Tris containing
the appropriate deuterated standards, followed by two
rounds of centrifugation at 3000 g. The chloroform phase
was collected, dried, and the lipids resuspended in 2:1
chloroform:methanol and quantified on a Thermo TSQ
Quantum Access Triple Quadropole mass spectrometer.
Structure modeling and analysis
A FAAH2 model structure was produced by threading
the sequence of wild-type human FAAH2 onto a hu-
manized rat FAAH1 template structure (PDB ID:2WAP)
in Modeller 9.13 [31]. The p.Ala458Ser mutation was
modeled in Coot [32] with a rotamer selected to
minimize steric clashes as determined by Molprobity
[33]. Atoms within 3.5 Å and capable of forming hydro-
gen bonds with the hydroxyl group of p.Ser458 were
identified in Coot.
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and LC-MS/MS compound identification and quantification
We have applied a targeted quantitative metabolomics
approach to analyze the serum samples using a combin-
ation of direct injection mass spectrometry (Absolute-
IDQ™ Kit) with a reverse-phase LC-MS/MS Kit. The Kit
is a commercially available assay from BIOCRATES Life
Sciences AG (Austria). This kit, in combination with an
ABI 4000 Q-Trap (Applied Biosystems/MDS Sciex) mass
spectrometer, can be used for the targeted identification
and quantification of up to 180 different endogenous
metabolites including amino acids, acylcarnitines, bio-
genic amines, glycerophospholipids, sphingolipids and
sugars. The method used combines the derivatization
and extraction of analytes, and the selective mass-
spectrometric detection using multiple reaction moni-
toring (MRM) pairs. Isotope-labeled internal standards
and other internal standards are integrated in Kit plate
filter for metabolite quantification. The AbsoluteIDQ kit
contains a 96 deep-well plate with a filter plate attached
with sealing tape, and reagents and solvents used to pre-
pare the plate assay. First 14 wells in the Kit were used
for one blank, three zero samples, seven standards and
three quality control samples provided with each Kit. All
the serum samples were analyzed with the AbsoluteIDQ
kit using the protocol described in the AbsoluteIDQ user
manual. Briefly, serum samples were thawed on ice and
were vortexed and centrifuged at 13,000 × g. 10 μL of
each serum sample was loaded onto the center of the fil-
ter on the upper 96-well kit plate and dried in a stream
of nitrogen. Subsequently, 20 μL of a 5% solution of
phenyl-isothiocyanate was added for derivatization. After
incubation, the filter spots were dried again using an evap-
orator. Extraction of the metabolites was then achieved by
adding 300 μL methanol containing 5 mM ammonium
acetate. The extracts were obtained by centrifugation into
the lower 96-deep well plate, followed by a dilution step
with kit MS running solvent. Mass spectrometric analysis
was performed on an API4000 Qtrap® tandem mass spec-
trometry instrument (Applied Biosystems/MDS Analytical
Technologies, Foster City, CA) equipped with a solvent de-
livery system. The samples were delivered to the mass
spectrometer by a LC method followed by a direct injec-
tion (DI) method. The Biocrates MetIQ software was used
to control the entire assay workflow, from sample registra-
tion to automated calculation of metabolite concentrations
to the export of data into other data analysis programs. A
targeted profiling scheme was used to quantitatively screen
for known small molecule metabolites using multiple reac-
tion monitoring, neutral loss and precursor ion scans.
Results
Our patient (Subject II-1 in Figure 1) is a 25 year old
male who was born after an uncomplicated pregnancyfrom healthy non-consanguinous Caucasian parents. He
has a healthy brother and extended family history is
negative for similarly affected children or neuropsychi-
atric disorders. He presented as a neonate with hypo-
tonia, feeding difficulties and central apneic episodes
associated with an abnormal EEG which demonstrated
an overabundance of multifocal sharp waves against a
discontinuous asynchronous background that was ab-
normal for age. He had delayed motor and language
milestones and as a child was noted to have ocular
apraxia with a moderate to severe dysarthria made worse
by a mechanically based limitation in jaw opening.
He developed autistic features by the age of 3 years
and was diagnosed with an anxiety disorder at the age of
7 which responded to selective serotonin reuptake inhib-
itors. He remained stable until the age of 22 years when
he presented with recurrent psychogenic seizures char-
acterized by episodic atonic collapses heralded by a flut-
tering of his eyes and then becoming unable to speak or
move but retaining full awareness of his environment.
These episodes would last seconds up to 30 minutes and
occurred once to several times per day. Psychosocial
functioning until age 22 years had been relatively stable.
He completed school with the help of a scribe because
of problems with hand co-ordination. At the time of
presentation he was enrolled in university and was
studying to obtain a joint degree in accounting and fi-
nancing with similar assistance.
His neurological examination at the age of 25 years
demonstrated preserved neurocognitive abilities, severe
dysarthria, a supranuclear vertical gaze palsy, left facial
hypoplasia, limited jaw opening (despite MRI confirmed
normal temporomandibular joint anatomy showing only
very limited anterior translation of the mandibular head
on mouth opening), limited lateral movement of his
tongue but no associated tongue weakness, bilaterally re-
duced fine motor movements, a mild left spastic gait
and a bilateral action tremor. Mental status examination
was significant for a stereotypy characterized by the
placement of his fisted hands against his head and
mostly surfacing during periods of emotional arousal.
His mood was initially reported as euthymic but subse-
quently he became aware of an underlying depression,
which was intermittently associated with suicidal idea-
tion and anxiety often preceding his psychogenic
seizures.
Brain magnetic resonance imaging (MRI) at the age of
10 years showed delayed myelination. Repeat MRI at the
age of 22 years was unremarkable other than a promin-
ent cisterna magna.
Over time it became clear that his psychogenic sei-
zures represented conversion reactions provoked by se-
vere anxiety from a decompensation into a major
depressive illness. As his illness unfolded, his episodes
Figure 1 Pedigree and Sanger sequencing of a patient with FAAH2 mutation. Pedigree information for our patient and Sanger sequencing
results are shown. The pedigree is consistent with X-linked recessive inheritance as the mother is clinically unaffected.
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were manifestations of emotional conflicts. He had a
partial response to the combination of sertraline, bupro-
pion and quetiapine combined with psychotherapy.
Biochemical work up was negative except for an ab-
normal whole blood acylcarnitine profile which showed
persistent 10-fold elevations in medium chain species
with lesser elevations in short and long chain species.
Although the patient did not have clinical features to
suggest other disorders which could cause this profile in-
cluding multiple acylCoA dehydrogenase deficiency
(MADD [MIM 231680]), and defects in riboflavin me-
tabolism, these were excluded through single gene se-
quencing. The patient did not have a pattern of clinical
deterioration to suggest Niemann-Pick Disease type C
(NPC1 [MIM 257220] and NPC2 [607625]) but, given
the gaze palsy, defects in NPC1 and NPC2 were ex-
cluded through single gene sequencing.
Whole exome sequencing was performed as described
in the Methods section. We analyzed the variants pre-
dicted to be functional (missense, nonsense and frameshift
changes, as well as in-frame deletions and splice-site ef-
fects) under a series of inheritance models. We only fo-
cused on the variants not present in the clinically
unaffected brother. We identified six hemizygous candi-
date genes (FAAH2, KIAA1210, AKAP14, TXLNG,
ZMYM3 and NRK), five compound heterozygous candi-
date genes (MUC16, CFTR, TTN, KEAP1 and HIVEP2)
and one gene (MYO1H) affected by a de novo mutation
(see Additional file 1: Table S1). All 12 genes wereevaluated to see if any of the candidates could be associ-
ated with the neuropsychiatric phenotype and the abnor-
mal acylcarnitine profile, which was present in this
patient. The hemizygous variant located on the X-
chromosome affecting FAAH2 (hg19: g.57475100G > T)
was considered a very strong candidate in that it harbored
a missense mutation c.1372G > T (p.Ala458Ser), FAAH2
is known to play a role in lipid metabolism [21] and al-
terations in endocannabinoid metabolism have been
documented in many different psychiatric disorders
[6]. None of the other candidate genes are known to
play a role in lipid metabolism and psychiatric diseases
(Additional file 1: Table S1). This variant was con-
firmed by Sanger sequencing (Figure 1) as present in
the index case and mother (who had a normal acylcar-
nitine profile) and was absent in the father and un-
affected brother. The variant is reported in dbSNP
(version 138) as heterozygous (rs147173444), not
hemi/homozygous, with a low frequency 0.00022, but
unreported in NHLBI ESP and our in-house genome
database. Among the 61,486 unrelated individuals se-
quenced as part of various disease-specific and population
genetic studies available at the Exome Aggregation Con-
sortium (ExAC) website (accessed January 05, 2015), the
g.57475100G > T allele was observed in 104 out of 122778
allele counts but of those, only 24 are reported as hemi/
homozygous. Of note, this dataset includes cohorts of pa-
tients with mental illnesses. The variant is predicted dam-
aging via all tested prediction tools, including SIFT [34]
(score 0.041), PROVEAN ([35]; score −2.85) and
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to the Combined Annotation Dependent Depletion
(CADD) [37] scoring system, the variant has a Phred-
score of 16.93, considered as likely functionally impactful.
X-inactivation studies showed random X-inactivation in
the mother.
We subsequently generated and expressed the
p.Ala458Ser FAAH2 mutant in human 293T cells to ex-
plore the functional consequences of the p.Ala458Ser
mutation found in our patient. Despite repeated efforts
to enhance its expression, the p.Ala458Ser mutant was
consistently expressed at a reduced level (~30-40%)
compared to the wild type (WT) enzyme (Figure 2A).
Enzymatic analysis using two established FAAH2 sub-
strates, AEA and palmitoylethanolamide (PEA), re-
vealed that substrate hydrolysis by the p.Ala458Ser
mutant was significantly lower compared with the WT
enzyme (Figure 2B). The importance of alanine at p.458
is supported by its high conservation among the ami-
dase signature family of enzymes and absolute conser-
vation among FAAH2 orthologs (Additional file 2:
Figures S1 and S2). Alanine at p.458 in FAAH2 corre-
sponds to alanine at p.478 in FAAH1. We confirmed
that similar to FAAH2, the p.Ala478Ser FAAH1 mutant
possessed reduced catalytic activity (Figure 2C and D)
despite similar levels of expression, indicating that the
importance of this residue is not confined to FAAH2
and may extend to many members of the amidase sig-
nature family.
Alanine at p.458 is situated in a region that is in
close proximity to a loop region that houses p.Ser206,
one of the two active site serines in this enzyme class
([38]; Figure 3A). Molecular modeling suggests that
substitution of this residue with a serine may result in
additional hydrogen bonding interactions with sur-
rounding residues (e.g., p.Asn195) (Figure 3B). To
examine the importance of potential hydrogen bonding
interactions induced by the serine mutation, we mu-
tated alanine at p.458 to cysteine or valine, residues
that possess reduced or no hydrogen bonding poten-
tial, respectively. Surprisingly, despite robust expres-
sion, the p.Ala458Cys FAAH2 mutant displayed
catalytic activity that was similar in magnitude to the
p.Ala458Ser mutation (Figure 2A and B). Furthermore,
the p.Ala458Val mutant was expressed at a similar level as
the p.Ala458Ser mutant but possessed only marginally
higher catalytic activity, suggesting that substitution of ala-
nine at p.458 with bulkier amino acids, rather than add-
itional hydrogen bonding potential, may account for the
defects in FAAH2 activity in the mutants. Collectively, our
data establish alanine at p.458 as a residue that is essential
for substrate hydrolysis by FAAH2 and its importance is
highlighted by its high degree of conservation among ami-
dase signature enzymes.To explore effects of the FAAH2 mutation in patient
tissues, we examined AEA hydrolysis in cultured fibro-
blasts derived from our patient and a corresponding un-
affected control. Importantly, human fibroblasts do not
express FAAH1 (Figure 2E) but robustly express FAAH2
(Figure 2F), thus permitting an examination of this
FAAH2 mutation upon endocannabinoid metabolism.
AEA hydrolysis by fibroblasts bearing the p.Ala458Ser
mutation was significantly lower compared to unaffected
control fibroblasts (Figure 2G). Treatment of fibroblasts
with URB597, a selective dual FAAH1 and FAAH2 in-
hibitor [21,39], completely abolished AEA hydrolysis,
thereby confirming that AEA hydrolysis observed in fi-
broblasts was mediated by FAAH2 (Figure 2G).
To further substantiate the functional consequences of
the p.Ala458Ser mutation, we profiled the levels of the
endocannabinoids, AEA and 2-AG, and related N-
acylethanolamines, PEA and oleoylethanolamide (OEA),
in fibroblasts from our patient and two unrelated con-
trols shown in Additional file 2: Figure S3. Our results
reveal an elevation of AEA levels in the affected fibro-
blasts compared to the controls and provide further sup-
port of defective AEA hydrolysis by the FAAH2
p.Ala458Ser mutant. Furthermore, detailed lipidomic
analysis on serum from our patient showed perturba-
tions in multiple lipid species, with elevations in many
long chain species, most marked with lyso-phosphatidyl
choline as shown in Additional file 3: Table S2.
Discussion
We have demonstrated for the first time functional im-
pairments in FAAH2 activity in a patient with neurologic
and psychiatric symptoms who has a missense mutation
in FAAH2 that results in reduced enzyme activity. Sev-
eral lines of evidence point to a possible causal relation-
ship between defects in FAAH2 activity and the
psychiatric/neurologic phenotype in this patient. Reduced
activity of FAAH1 has been associated with other psychi-
atric illnesses [20] so it is reasonable to hypothesize that
alterations in the ECS caused by changes in FAAH2 ac-
tivity could also have psychiatric consequences. Our
patient has a phenotype dominated by anxiety symp-
toms and alterations in the ECS have been shown in
many psychiatric conditions including anxiety for
which a biphasic response (low levels of ECS activation
reducing anxiety and higher levels of activation in-
creasing anxiety) has been demonstrated [6]. Our pa-
tient has some mild specific learning disabilities and
FAAH1 knock-out mice have been shown to exhibit
learning deficits that can be reversed with the canna-
binoid receptor antagonist rimonabant [40]. Our pa-
tient had early onset of autistic features and several lines
of evidence link alterations in the ECS to autistic symp-
toms [16]. Neuroligin-3 mutations associated with autism
Figure 2 Functional analysis of FAAH2 mutations. (A) Expression of FLAG-tagged FAAH2 and FAAH2 mutants in 293T cells. The blots were
probed with anti-FLAG (Sigma # F1804) and anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH, Abcam #ab8245) antibodies. (B) AEA and
PEA hydrolysis by cell homogenates expressing FAAH2 and FAAH2 mutants. Results were analyzed using one-way ANOVA followed by Dunnett’s
post hoc analysis. *, p < 0.05; **, p < 0.01; ***, p < 0.001 (n = 5–7). (C) Expression of FLAG-tagged FAAH1 and the FAAH1 p.Ala478Ser mutant in
293T cells. Blots were probed with an anti-FLAG antibody. (D) AEA hydrolysis by WT and p.Ala478Ser FAAH1 ***, p < 0.001 (n = 4). (E) Human
fibroblasts do not express FAAH1. Fibroblasts from a control patient and the FAAH2 p.Ala458Ser affected patient were probed with anti-FAAH1
antibodies (Abcam #ab54615). FAAH1 transfected and untransfected 293T cells served as controls. (F) Expression of FAAH2 in fibroblasts from the
affected p.Ala458Ser patient and an unaffected control. Blots were probed with an anti-FAAH2 antibody (Abcam, ab103724). (G) AEA hydrolysis
by control fibroblasts and affected FAAH2 p.Ala458Ser fibroblasts in the absence and presence of URB597. *, p < 0.05; **, p < 0.01 versus unaffected
control. #, p < 0.05 versus affected control (n = 4).
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Figure 3 Modeled structural environments of the disease-
causing mutations in FAAH2. Modeled structure of human FAAH2.
The protein backbone is shown as a cartoon (white) with the side
chains of A458 (green) and the catalytic triad residues (K131, S206,
S230; orange) shown as sticks. (B) Additional interactions formed by
the p.Ala458Ser mutation. Potential hydrogen bonds are observed
between the side chain of Ser458 (green sticks) and the side chain of
N195 or the carbonyl oxygens of I202 and F237 (cyan sticks). Distances
in angstroms between interacting atoms are shown in dark red.
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mice also have a behavioral phenotype characterized as re-
duced emotionality [41]. It must be acknowledged how-
ever that mice lack FAAH2 [21] and that FAAH1 and
FAAH2 have different substrate affinities [21], so any
comparison of the human FAAH2 deficiency phenotype
to that of the FAAH1 knock-out mouse must be inter-
preted with caution.
Our patient had a vertical supranuclear gaze palsy
which we postulate could be related to reduced FAAH2
activity within the intracellular lipid droplets that serve
as sites of cholesterol ester storage and mobilization
[22]. FAAH2 is expressed in a number of human tissues
[4]. Although the primary function of FAAH2 in these
tissues remains unclear, lipid droplet localization is re-
quired for active hydrolysis of endocannabinoids by
FAAH2 [22]. Lipid droplets are an important site of tria-
cylglyeride and cholesteryl-ester storage and trafficking
and endocannabinoid metabolism by FAAH2 may influ-
ence these pathways. Intracellular trafficking of cholesteroland some fatty acids occurs through a pathway involving
the Niemann Pick C1 transporter and modulation of
its function alters the eicosanoid pool in cells [42]. In
Niemann Pick C, there is defective intracellular lipid
trafficking and patients with this condition develop
vertical supranuclear gaze palsy over time [43]. There-
fore, we hypothesize that a reduction of FAAH2 activ-
ity as a result of the mutation in our patient could
alter the levels of FAAH2 substrates and products and
feedback to alter cholesterol trafficking at the level of
the lipid droplet and lead to this unusual clinical
feature.
The persistent elevations of medium chain acylcarni-
tines in both serum and bloodspot in our patient were
suggestive of a dysregulation of fatty acid oxidation
(FAO). The pattern was not suggestive of an enzyme-
specific block in beta-oxidation but rather was reminiscent
of the pattern seen secondary to medium chain triglycer-
ide supplementation, with elevations resulting from
increased flux through the pathway. The role of endocan-
nabinoids in FAO is complex with both agonistic and an-
tagonistic effects depending on the receptor system and
tissue involved. In muscle cells, agonists of the type 2 can-
nabinoid receptor have been shown to promote FAO
through transcriptional upregulation of carnitine palmi-
toyltransferase I [44]. Such an effect would be consistent
with the acylcarnitine pattern seen in our patient (in-
creased flux).
We are aware of 2 other citations where FAAH2 muta-
tions have been identified in human patients with neuro-
logic diseases. In a study of humans with autism
spectrum disorder, 2 males with validated nonsense mu-
tations in FAAH2 are listed in a supplementary appendix
[27]. In a study of patients with X-linked intellectual dis-
ability [26], two brothers were identified with a deletion
involving FAAH2. Clinical and biochemical details of the
patients were not provided in either citation (and efforts
to obtain such information were not successful); further-
more, the impact of the mutations on enzymatic activity
were not quantified. The p.Ala458Ser mutation was
found in 104 alleles in the Exome Aggregation Consor-
tium website (accessed January 5 2015) but, as the pedi-
gree of our patient suggests an X-linked recessive
pattern of inheritance, only the 24 male alleles carrying
this mutation are relevant to our case. The fact that this
mutation has been identified in other patients in this large
data set is not surprising because the Exome Aggregation
Consortium includes patients with mental illnesses. If
FAAH2 mutations are indeed related to common condi-
tions like autism spectrum disorder and mental illness,
then it could be expected that similar mutations could be
identified in multiple patients. Further research however
is required to prove a causal relationship between FAAH2
mutations and these common conditions.
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FAAH2 activity could contribute to neurological symp-
toms in humans has limitations. Information is conflict-
ing on the distribution of FAAH2 in human brain. Some
reports (www.brainspan.org) but not others [21] have
been able to identify FAAH2 transcripts in human brain.
Much of the information supporting this hypothesis has
been derived from FAAH1 knockout mice and, as mice
lack FAAH2 [21] and FAAH1 and FAAH2 have different
substrate affinities [21], the effects of the single gene
knockout in mice may not be applicable to humans.
Clinical details from other patients with mutations in
FAAH2 are needed to see if the unusual clinical features
seen in our patient (supranuclear gaze palsy, abnormal
acylcarnitine profile) are a consistent feature of the
phenotype.
Conclusions
This is the first comprehensive clinical and biochemical
report of FAAH2 deficiency in humans. We propose that
the neuropsychiatric features may result from FAAH2
deficiency and identification and characterization of
more cases are required to delineate the full spectrum
and to further confirm the demonstrated relation be-
tween symptom severity and the degree of enzymatic
impairment. Areas deserving further research include
FAAH2 distribution and ECS actions in human brain
(www.brainspan.org) as well as the precise functions of
FAAH2 substrates –both known and unknown. Finally,
FAAH2 mutations should be considered in the differen-
tial diagnosis of patients with undiagnosed neuropsychi-
atric impairment.
Additional files
Additional file 1: Table S1. Variants identified on whole exome
sequencing in our male patient with neurologic and psychiatric features.
Additional file 2: Figure S1. Sequence comparison of selected amidase
signature family members. The sequences of Bacillus subtilis Glu-tRNAGln
amidotransferase subunit A, Pseudomonas putida mandelamide hydrolase,
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